**Table 1: Baseline characteristics.**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Latin American (n=956)** | | **Non–Latin American (n=17157)** | | **p-value** |
| Age, years, mean (SD) | 71.6 | (9.0) | 71.5 | (8.7) | 0.55 |
| Weight, kg, mean (SD) | 77.4 | (16.6) | 82.9 | (19.7) | <0.001 |
| SBP, mmHg, mean (SD) | 131.3 | (18.2) | 131.0 | (17.4) | 0.54 |
| DBP, mmHg, mean (SD) | 80.0 | (10.8) | 76.9 | (10.5) | <0.001 |
| Male, n (%) | 559 | (58.5) | 10955 | (63.9) | <0.001 |
| Paroxysmal AF, n (%) | 115 | (12.0) | 5828 | (34.0) | <0.001  <0.001  <0.001 |
| Persistent AF, n (%) | 165 | (17.3) | 5624 | (32.8) | <0.001 |
| Permanent AF, n (%) | 676 | (70.7) | 5699 | (33.2) | <0.001 |
| CRCL, mL/min, mean (SD) | 63.1 | (24.1) | 73.3 | (27.5) | <0.001 |
| CHADS2 score, mean (SD) | 2.2 | (1.0) | 2.1 | (1.1) | 0.54 |
| CHA2DS2-VASc score, mean (SD) | 3.5 | (1.3) | 3.6 | (1.4) | 0.52 |
| Previous stroke, n (%) | 110 | (11.5) | 2163 | (12.6) | 0.34 |
| Previous MI, n (%) | 85 | (8.9) | 2920 | (17.0) | <0.001 |
| Previous CAD, n (%) | 122 | (12.8) | 4912 | (28.6) | <0.001 |
| Heart failure, n (%) | 393 | (41.1) | 5400 | (31.5) | <0.001 |
| Diabetes mellitus, n (%) | 155 | (16.2) | 4066 | (23.7) | <0.001 |
| Hypertension, n (%) | 787 | (82.3) | 13496 | (78.7) | 0.008 |
| Baseline medication |  |  |  |  |  |
| Aspirin, n (%) | 467 | (48.8) | 6704 | (39.1) | <0.001 |
| ARB, n (%) | 192 | (20.1) | 4144 | (24.2) | 0.005 |
| ACE inhibitor, n (%) | 534 | (55.9) | 7589 | (44.2) | <0.001 |
| Beta-blocker, n (%) | 533 | (55.8) | 10866 | (63.3) | <0.001 |
| Amiodarone, n (%) | 184 | (19.2) | 1792 | (10.4) | <0.001 |
| Verapamil, n (%) | 26 | (2.7) | 1045 | (6.1) | <0.001 |
| Proton pump inhibitor, n (%) | 53 | (5.5) | 2516 | (14.7) | <0.001 |
| H2 blocker, n (%) | 53 | (5.5) | 707 | (4.1) | 0.04 |
| VKA use at randomization, n (%) | 421 | (44.0) | 10768 | (62.8) | <0.001 |

ACE, angiotensin-converting enzyme; AF, atrial fibrillation; ARB, angiotensin receptor blocker; CAD, coronary artery disease; CRCL, creatinine clearance; DBP, diastolic blood pressure; SBP, systolic blood pressure; SD, standard deviation; VKA, vitamin K antagonist.

CHADS2, cardiac failure, hypertension, age ≥75 years, diabetes, prior stroke [doubled]; CHA2DS2-VASc (cardiac failure, hypertension, age ≥75 years [doubled], diabetes, prior stroke [doubled]-vascular disease, age 65–74 years and sex category [female]).